SG11202113226QA - Antiarrhythmic formulation - Google Patents
Antiarrhythmic formulationInfo
- Publication number
- SG11202113226QA SG11202113226QA SG11202113226QA SG11202113226QA SG11202113226QA SG 11202113226Q A SG11202113226Q A SG 11202113226QA SG 11202113226Q A SG11202113226Q A SG 11202113226QA SG 11202113226Q A SG11202113226Q A SG 11202113226QA SG 11202113226Q A SG11202113226Q A SG 11202113226QA
- Authority
- SG
- Singapore
- Prior art keywords
- antiarrhythmic
- formulation
- antiarrhythmic formulation
- Prior art date
Links
- 230000003288 anthiarrhythmic effect Effects 0.000 title 1
- 239000003416 antiarrhythmic agent Substances 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962881689P | 2019-08-01 | 2019-08-01 | |
US16/901,909 US11007185B2 (en) | 2019-08-01 | 2020-06-15 | Antiarrhythmic formulation |
US16/901,941 US11020384B2 (en) | 2019-08-01 | 2020-06-15 | Antiarrhythmic formulation |
PCT/US2020/044291 WO2021022058A2 (fr) | 2019-08-01 | 2020-07-30 | Formulation antiarythmique |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202113226QA true SG11202113226QA (en) | 2021-12-30 |
Family
ID=74229279
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202113226QA SG11202113226QA (en) | 2019-08-01 | 2020-07-30 | Antiarrhythmic formulation |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP4007576A4 (fr) |
JP (2) | JP7190077B2 (fr) |
KR (2) | KR102491733B1 (fr) |
CN (1) | CN114144177A (fr) |
AU (3) | AU2020323594B2 (fr) |
CA (1) | CA3139748A1 (fr) |
IL (2) | IL290088B2 (fr) |
SG (1) | SG11202113226QA (fr) |
WO (1) | WO2021022058A2 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11007185B2 (en) | 2019-08-01 | 2021-05-18 | Incarda Therapeutics, Inc. | Antiarrhythmic formulation |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2176712C (fr) * | 1993-11-16 | 2000-05-23 | Mantripragada Sankaram | Vesticules a taux controle de liberation des principes actifs |
US20070178050A1 (en) * | 2005-12-20 | 2007-08-02 | Verus Pharmaceuticals, Inc. | Methods and systems for the delivery of corticosteroids having an increased lung depositon |
WO2010107964A1 (fr) | 2009-03-18 | 2010-09-23 | Pleiades Cardio-Therapeutics, Inc. | Doses unitaires, aérosols, trousses, et méthodes pour traiter des affections cardiaques par administration pulmonaire |
CA3012333A1 (fr) * | 2016-02-01 | 2017-08-10 | Incarda Therapeutics, Inc. | Combinaison de la surveillance electronique avec une therapie pharmacologique par inhalation pour gerer des arythmies cardiaques dont la fibrillation auriculaire |
KR20200003199A (ko) * | 2017-05-10 | 2020-01-08 | 인카다 테라퓨틱스, 인크. | 폐 투여에 의해 심장 병태를 치료하기 위한 단위 용량, 에어로졸, 키트 및 방법 |
AU2018265624A1 (en) * | 2017-05-11 | 2019-12-05 | Steadymed, Ltd. | Enhanced solubility drug-containing formulations |
GB2564444B (en) * | 2017-07-10 | 2020-09-16 | Syri Ltd | Liquid pharmaceutical composition of flecainide |
-
2020
- 2020-07-30 SG SG11202113226QA patent/SG11202113226QA/en unknown
- 2020-07-30 IL IL290088A patent/IL290088B2/en unknown
- 2020-07-30 IL IL303094A patent/IL303094A/en unknown
- 2020-07-30 WO PCT/US2020/044291 patent/WO2021022058A2/fr unknown
- 2020-07-30 JP JP2022506507A patent/JP7190077B2/ja active Active
- 2020-07-30 CA CA3139748A patent/CA3139748A1/fr active Pending
- 2020-07-30 KR KR1020227003421A patent/KR102491733B1/ko active IP Right Grant
- 2020-07-30 AU AU2020323594A patent/AU2020323594B2/en active Active
- 2020-07-30 KR KR1020237001970A patent/KR20230014882A/ko active Search and Examination
- 2020-07-30 CN CN202080052432.0A patent/CN114144177A/zh active Pending
- 2020-07-30 EP EP20848179.6A patent/EP4007576A4/fr active Pending
-
2022
- 2022-04-29 AU AU2022202842A patent/AU2022202842B2/en active Active
- 2022-12-02 JP JP2022193405A patent/JP2023022251A/ja active Pending
-
2024
- 2024-02-29 AU AU2024201359A patent/AU2024201359A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2024201359A1 (en) | 2024-03-21 |
AU2022202842A1 (en) | 2022-05-19 |
WO2021022058A2 (fr) | 2021-02-04 |
JP2023022251A (ja) | 2023-02-14 |
IL290088B1 (en) | 2023-06-01 |
AU2020323594A1 (en) | 2021-12-23 |
KR102491733B1 (ko) | 2023-01-27 |
CA3139748A1 (fr) | 2021-02-04 |
IL290088B2 (en) | 2023-10-01 |
WO2021022058A3 (fr) | 2021-04-08 |
JP7190077B2 (ja) | 2022-12-14 |
EP4007576A4 (fr) | 2023-05-10 |
IL303094A (en) | 2023-07-01 |
IL290088A (en) | 2022-03-01 |
AU2020323594B2 (en) | 2022-02-03 |
CN114144177A (zh) | 2022-03-04 |
JP2022533477A (ja) | 2022-07-22 |
KR20220025071A (ko) | 2022-03-03 |
EP4007576A2 (fr) | 2022-06-08 |
KR20230014882A (ko) | 2023-01-30 |
AU2022202842B2 (en) | 2024-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL276011A (en) | Formulation containing group b adenovirus | |
IL282617A (en) | Aerosol formulation | |
IL282523A (en) | Aerosol formulation | |
IL290447A (en) | A pharmaceutical preparation containing ansiphantrine | |
IL282567A (en) | Aerosol formulation | |
IL282589A (en) | Aerosol formulation | |
GB201816447D0 (en) | Formulation | |
IL282461A (en) | Aerosol formulation | |
IL282697A (en) | Aerosol formulation | |
IL282392A (en) | Aerosol formulation | |
IL284688A (en) | formulation | |
IL290088A (en) | Antiarrhythmic formulation | |
GB201807312D0 (en) | Formulation | |
GB201913232D0 (en) | Aerosolisable formulation | |
IL280138A (en) | Spray formulation | |
GB201813229D0 (en) | Formulation | |
GB2599912B (en) | New formulation | |
GB2587402B (en) | Formulation | |
GB201906242D0 (en) | Aerosolisable formulation | |
GB201900658D0 (en) | Formulation | |
GB202115303D0 (en) | New formulation | |
GB202108181D0 (en) | New formulation | |
GB202006008D0 (en) | Aerosolisable formulation | |
GB202005340D0 (en) | Formulation | |
GB202003048D0 (en) | Formulation |